Covers hair and nail findings, vision loss lawsuits both drugmakers dispute, and new WHO guidance against drug treatment for obesity in kids under 10.
Recap by typeshit. Full story at MIT Technology Review.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
In the 274-person TOGETHER-PsO trial, the combo changed 482 blood proteins versus 140 with Taltz alone, which Lilly says hints at a link between psoriasis and obesity.
Amgen shares are up about 24% this year on interest in its obesity candidate MariTide. One bearish take flags manufacturing scale and a crowded GLP-1 market.
Loading…